Cargando…
An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines
The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term admin...
Autores principales: | Zaccagnino, Angela, Vynnytska-Myronovska, Bozhena, Stöckle, Michael, Junker, Kerstin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058472/ https://www.ncbi.nlm.nih.gov/pubmed/36982721 http://dx.doi.org/10.3390/ijms24065648 |
Ejemplares similares
-
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability
por: Kurlishchuk, Yuliya, et al.
Publicado: (2016) -
Characterization of CD147, CA9, and CD70 as Tumor-Specific Markers on Extracellular Vesicles in Clear Cell Renal Cell Carcinoma
por: Himbert, Dirk, et al.
Publicado: (2020) -
Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017) -
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018) -
Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
por: Ishibashi, Kei, et al.
Publicado: (2017)